A key element of this portfolio is the QIAseq FastSelect RNA Removal Kit which provides a novel solution for scientists to target RNA types that are irrelevant to their research and remove them from RNA-seq libraries for next-generation sequencing.
The global market size for library preparation kits for RNA-seq is believed to be about USD 400m.
In addition to a highly competitive and differentiated line of RNA-seq solutions, several other Qiagen solutions for accurate, efficient NGS will be showcased at ASHG 2018, the conference of the American Society of Human Genetics from October 16-20 in San Diego.
In addition, more than 15 studies relying upon QIAseq solutions, the GeneReader NGS System and other Qiagen Sample to Insight products will be presented in ASHG 2018 scientific sessions, demonstrating the unique positioning of Qiagen in this rapidly growing market of next generation sequencing.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients